Pixium Vision (PIX)

Business description

Pixium Vision develops retinal implants for patients with severe vision loss. Its lead product Iris is an epi-retinal implant, which received CE mark approval in 2016; a sub-retinal implant (Prima) is expected to start a human study in 2017 .

Stock data

Market cap.€70.7m
Last close€5.35
High / Low (52 weeks)€7.3 / €5.3
Stock market listingEU
Forecast net debt (€m)1.8
Forecast gearing ratio (%)15
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(4.6)(11.6)(19.3)
Relative *(7.6)(11.7)(31.5)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acarix Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma ASLAN Pharmaceuticals
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
BrainStorm Cell Therapeutics BTG
C4X Discovery Holdings Can-Fite BioPharma
Capstone Therapeutics Carmat
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Clal Biotechnology
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
co.don AG Collplant Holdings
Consort Medical Corium International
Crescendo Crossject
CSL Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Heat Biologics Inc. Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings Immunovia
ImmuPharma Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Intec Pharma
International Stem Cell Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MGC Pharmaceuticals
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt Novogen
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Orgenesis
Oryzon Genomics Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
PDL BioPharma Pharmacyclics
PharmaMar Pharmaxis
Pharming Group Photocure
Phylogica Pluristem Therapeutics
Prescient Therapeutics Prima BioMed
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
PsiOxus QRxPharma
Quantum Genomics Quantum Pharmaceuticals
Race Oncology RedHill Biopharma
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Rovi
RXi Pharmaceuticals Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
Targovax TearLab Corp
Tekmira TESARO
Theraclion Therapix Biosciences
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics Trimel Pharmaceuticals
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xbrane Biopharma Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

BRIEF-Pixium Vision implants 10 patients with Iris II

Wed, 11 Jan 2017 17:37:39 GMT

Pixium Vision Receives Clinical Trial Approval from UK Regulatory Authority ...

Tue, 31 May 2016 06:56:15 GMT

Pixium Vision announces CE market approval of IRIS

Mon, 25 Jul 2016 05:01:32 GMT

Pixium Vision Advances in Discussions with FDA for a Feasibility Study with ...

Tue, 13 Jun 2017 05:03:18 GMT

Pixium Vision Receives NUB Innovation Reimbursement Status-1 for 150 Electrode ...

Tue, 14 Feb 2017 06:00:00 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2015A 3.3 (14.6) (15.6) (122.88) N/A N/A
2016A 2.5 (11.4) (12.4) (97.60) N/A N/A
2017E 3.8 (10.8) (12.6) (95.23) N/A N/A
2018E 14.9 (13.6) (17.9) (132.86) N/A N/A

Last updated on 22/08/2017

Investment summary

Pixium Vision is developing two different retinal implant systems that transform images into electrical signals to elicit visual perception in patients with severe retinal disease. The devices consist of an implant and a pair of glasses with an embedded camera, and handheld control. Pixium received CE Mark approval for the Iris II epiretinal implant in July 2016. It is also conducting EU clinical trials with Iris II (10th and final implantation of the study completed in early 2017). Interim study data should assist reimbursement applications in EU markets. Positive pre-clinical data with Prima, a subretinal implant potentially providing better visual acuity than Iris II, should support first human testing in H217. Pixium held €14.9m in gross cash at 30 June 2017 and has up to €3m available in additional debt financing available.

Last updated on 06/09/2017

Industry outlook

Second Sight (EYES) is commercialising an epiretinal implant (Argus II) in the US and EU. The Iris II offers 150 electrodes (vs 60 on Argus II), potentially offering better vision, while also being the first potentially explantable (and upgradable) epiretinal implant. Prima is less surgically invasive and could potentially be a viable treatment option for macular degeneration patients.

Last updated on 06/09/2017

Key management

Khalid Ishaque, CEO
Didier Laurens , CFO

Company address

74 rue du Faubourg Saint-Antoine
Paris
75012
United Kingdom
+33 1 76 21 47 30
View website